Clarissa Parker to Disease Progression
This is a "connection" page, showing publications Clarissa Parker has written about Disease Progression.
Connection Strength
0.132
-
Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):51-8.
Score: 0.057
-
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):218-25.
Score: 0.025
-
Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003 Jan; 1(1):33-8.
Score: 0.020
-
Brain metastases. Curr Treat Options Oncol. 2001 Dec; 2(6):537-47.
Score: 0.019
-
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol. 2006 Jan; 1(1):52-60.
Score: 0.012